Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.

@article{Hatanaka2004InterferonalphaAA,
  title={Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.},
  author={Kazuteru Hatanaka and Koichi Suzuki and Yoshiaki Miura and Kimiko Yoshida and Shumpei Ohnami and Yukio Kitade and Teruhiko Yoshida and Kazunori Aoki},
  journal={The journal of gene medicine},
  year={2004},
  volume={6 10},
  pages={1139-48}
}
Interferon alpha (IFN-alpha) is used worldwide for the treatment of a variety of cancers. For pancreatic cancer, recent clinical trials using IFN-alpha in combination with standard chemotherapeutic drugs showed some antitumor activity of the cytokine, but the effect was not significant enough to enlist pancreatic cancer as a clinically effective target of IFN-alpha. In general, an improved therapeutic effect and safety are expected for cytokine therapy when given in a gene therapy context… CONTINUE READING